VYGR Reports $15.3M Q4 Revenue, $134.7M R&D Spend, $202M Cash Runway to 2028, VY1706 GLP Study Q1 2026, VY7523 MAD Completion, NeuroShuttle Proof-of-Concept
Voyager Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $3.79
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS